{"id":171015,"date":"2026-09-21T11:51:11","date_gmt":"2026-09-21T11:51:11","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/171015\/"},"modified":"2026-09-21T11:51:11","modified_gmt":"2026-09-21T11:51:11","slug":"why-is-nvo-stock-sliding-premarket-today","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/171015\/","title":{"rendered":"Why Is NVO Stock Sliding Premarket Today?"},"content":{"rendered":"<p>Novo Nordisk\u2019s long-term growth targets failed to ease investor concerns over Eli Lilly\u2019s obesity-drug lead, CagriSema\u2019s comparative performance and upcoming semaglutide patent expirations.\n<\/p>\n<p>Novo targets more than five new \u2018multi-blockbusters\u2019 by 2030 and over $23 billion in pipeline sales by 2035.CagriSema delivered 23% weight loss versus 25.5% for Lilly\u2019s Tirzepatide and failed to show non-inferiority in a Phase 3 trial.Semaglutide drives about 75% of Novo\u2019s 2026 sales, leaving the company exposed as key patents expire in major markets from 2030.<\/p>\n<p>Novo Nordisk (NVO) was in the spotlight on Monday after the drugmaker laid out its long-term growth targets but failed to give investors enough concrete near-term catalysts to ease concerns about competition from Eli Lilly (LLY).<\/p>\n<p>U.S.-listed\u00a0<a href=\"https:\/\/stocktwits.com\/symbol\/NVO\" rel=\"nofollow noopener\" target=\"_blank\">NVO shares<\/a> were down 5% at the time of writing. The stock has declined in seven of the last 10 sessions.<\/p>\n<p>Novo Targets More Than Five New Blockbusters<\/p>\n<p>At its Capital Markets Day, Novo said it aims to launch more than five \u201cmulti-blockbusters\u201d by 2030 spanning obesity, diabetes, liver diseases and blood and endocrine disorders. The pharmaceutical behemoth expects to generate more than DKK 150 billion ($23 billion) in pipeline sales by 2035. The company also expects 2026-2030 revenue growth to align with major pharmaceutical peers.<\/p>\n<p>However, several of Novo\u2019s potential growth drivers remain years from reaching the market, while the company is already losing ground to Lilly in obesity. Zepbound sales are expected to exceed Wegovy sales by more than $7 billion this year, <a class=\"st-link-external\" target=\"_blank\" rel=\"noopener noreferrer nofollow\" href=\"https:\/\/www.reuters.com\/legal\/litigation\/wegovy-maker-novo-faces-calls-map-out-strategy-beyond-weight-loss-drugs-2026-09-21\/\">according<\/a> to LSEG estimates cited by Reuters.<\/p>\n<p>\u201cInvestors are selling the shares because they are not seeing concrete news that could drive the stock higher,\u201d Nordnet investment economist Per Hansen said, <a class=\"st-link-external\" target=\"_blank\" rel=\"noopener noreferrer nofollow\" href=\"https:\/\/www.bloomberg.com\/news\/articles\/2026-09-21\/novo-touts-future-blockbuster-launches-disappointing-investors\">according<\/a> to Bloomberg.<\/p>\n<p>Analysts have also called for Novo to expand beyond its core obesity and diabetes businesses.<\/p>\n<p>\u201cThey \u2060should work harder in building a third leg &#8230; because in diabetes and obesity, they won&#8217;t find enough growth opportunities,\u201d Markus Manns, a portfolio manager at Union \u200bInvestment told Reuters.<\/p>\n<p>CagriSema Falls Short Against Lilly\u2019s Tirzepatide<\/p>\n<p>CagriSema, one of Novo\u2019s most important next-generation obesity treatments, has also raised concerns.<\/p>\n<p>In February, the drug produced 23% average weight loss after 84 weeks in a Phase 3 trial, compared with 25.5% for Tirzepatide, the active ingredient in Lilly\u2019s Zepbound. CagriSema failed the study\u2019s primary goal of demonstrating that it was non-inferior to Tirzepatide.<\/p>\n<p>Novo still expects an FDA decision on CagriSema for obesity in the final quarter of this year.<\/p>\n<p>Patent Expiry Pressure<\/p>\n<p>Novo could also be under pressure as patents protecting Semaglutide, the active ingredient in Wegovy and Ozempic, begin expiring in major markets in the early 2030s.<\/p>\n<p>Earlier this<a href=\"https:\/\/stocktwits.com\/news-articles\/markets\/equity\/nvo-stock-why-morgan-stanley-is-bearish-on-novo-nordisk-despite-its-weight-loss-drug-opportunity\/cZtXhhNRBGl\" rel=\"nofollow noopener\" target=\"_blank\">\u00a0month<\/a>, Morgan Stanley downgraded Novo to \u2018Underweight\u2019 from \u2018Equal Weight\u2019 with a $40 price target, highlighting patent risks. Semaglutide, which drives about 75% of Novo\u2019s 2026 sales, faces patent expirations in major markets over the coming years, opening the door to cheaper competition, the firm added.<\/p>\n<p>Retail Remains Bullish On NVO<\/p>\n<p>Despite the premarket slide, retail sentiment surrounding NVO on Stocktwits remained in the \u2018bullish\u2019 zone over the past 24 hours, amid \u2018high\u2019 message volumes.<\/p>\n<p>One user noted that the stock is \u201cextremely oversold.\u201d<\/p>\n<p>Another user said there is \u201cno basis for the drop.\u201d<\/p>\n<p>However, NVO shares are down more than 17% so far this year, significantly worse than LLY\u2019s 6.7% gains.<\/p>\n<p>Also read:<a href=\"https:\/\/stocktwits.com\/news-articles\/markets\/equity\/nasdaq-sp500-dow-futures-rise-ahead-of-trump-xi-summit-this-week-nvda-meta-crml-glnd-spcx-rklb-be-stocks-in-focus\/cZMR9EBRB4n\" rel=\"nofollow noopener\" target=\"_blank\">\u00a0Nasdaq, S&amp;P 500, Dow Futures Rise Ahead Of Trump-Xi Summit This Week: NVDA, META, CRML, GLND, SPCX, RKLB, BE Stocks In Focus<\/a><\/p>\n<p>For updates and corrections, email newsroom[at]stocktwits[dot]com<\/p>\n<p><a class=\"STButton_lg__XBy4m text-lg px-6 gap-2 STButton_button__ObG_J h-[--size] inline-flex flex-row items-center justify-center border rounded-full font-semibold whitespace-nowrap STButton_black-secondary__xIxs1 bg-white text-black border-secondary-button-border dark|bg-transparent dark|text-white hover|!bg-light-grey-6 dark|hover|!bg-dark-grey-5 p-2\" role=\"button\" tabindex=\"0\" type=\"button\" target=\"_blank\" rel=\"noopener nofollow\" href=\"https:\/\/news.google.com\/publications\/CAAqKQgKIiNDQklTRkFnTWFoQUtEbk4wYjJOcmRIZHBkSE11WTI5dEtBQVAB\"><img decoding=\"async\" alt=\"Follow on Google News\" src=\"https:\/\/chunks-prd.stocktwits-cdn.com\/_next\/static\/media\/google-news-icon.d9c2bfd1.svg\"\/><\/a><\/p>\n<p>Subscribe to Chart Art<\/p>\n<p>The best trade ideas and analysis from the Stocktwits community. Delivered daily by 8 pm ET.<\/p>\n<p><a rel=\"noopener nofollow\" target=\"_blank\" href=\"https:\/\/stocktwits.com\/about-newsroom\/\" class=\"NewsArticle_editorialLink__1BMFs hover|text-blue-ada underline w-full text-base\">Read about our editorial guidelines and ethics policy<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"Novo Nordisk\u2019s long-term growth targets failed to ease investor concerns over Eli Lilly\u2019s obesity-drug lead, CagriSema\u2019s comparative performance&hellip;\n","protected":false},"author":2,"featured_media":171016,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[271],"tags":[31662,14738,276,3860,77298,272,5487,78948,3859,9754,3102,25225,78949,689,1480,1910,277,3103],"class_list":["post-171015","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novo-nordisk","tag-biotech-stocks","tag-cagrisema","tag-eli-lilly","tag-lly","tag-novo-capital-markets-day","tag-novo-nordisk","tag-novo-nordisk-stock","tag-novo-patents","tag-nvo","tag-obesity-drugs","tag-ozempic","tag-pharma-stocks","tag-premarket-losers","tag-semaglutide","tag-tirzepatide","tag-wegovy","tag-weight-loss-drugs","tag-zepbound"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/117308888575125238","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/171015","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=171015"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/171015\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/171016"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=171015"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=171015"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=171015"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}